Keyword: Spark Therapeutics
Previously, despite repeated delays, tendered Spark shares stayed relatively stable at around 20%—until now.
Most Spark investors still haven't tendered their shares, despite word of FTC clearance—and the doctor feedback that may have made the difference.
The FTC staff on the Roche-Spark case has reportedly recommended approval of the deal, though top officials will also need to vote on it.
The FTC has dealt AbbVie and Allergan a "second request" in their proposed $63 billion merger, as Roche's Spark buy was delayed again by antitrust reviews.
When it comes to Roche and Spark’s $4.8 billion merger, delays are the norm. But even when there isn’t one, M&A watchers are keeping a close eye.
Cigna's new program that will cover Novartis' Zolgensma and Spark's Luxturna, both pricey gene therapies, at no cost to patients.
NICE's backing is a timely win for Novartis' gene therapy ambitions, as it's deeply embroiled in the Zolgensma data manipulation scandal.
Roche has pushed back its $114.50-per-share offer for Spark to Oct. 1—and U.S. and U.K. anti-competition review delays are still the problem.
The FTC's tough stance has analysts worried that regulatory red tape could tie up AbbVie’s $63 billion purchase of Allergan and other deals.
You might have lost count of how many times Roche has extended the tender offer period for shares of Spark Therapeutics. As of Wednesday, it's five.